Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis

References

• Falk R, Comenzo R, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898–909
   PubMed Web of Science ®Google Scholar
• Falk R, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000;45:107–37
   PubMedGoogle Scholar
• Duston M, Skinner M, Shirahama T, Cohen A. Diagnosis of amyloidosis: analysis of four years' experience. Am J Med 1987;82:412–4
   PubMedGoogle Scholar
• Shah K, Inoue Y, Mehra M. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006;166:1805–13
   PubMed Web of Science ®Google Scholar
• Ando Y, Nakamura M, Araki S. Transthyretinrelated familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057–62
   PubMed Web of Science ®Google Scholar
• Dubrey S, Cha K, Skinner M, LaValley M, Falk R. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78:74–82
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta C, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203–12
   PubMed Web of Science ®Google Scholar
• Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440–5
   PubMed Web of Science ®Google Scholar
• Hlatky M, Heidenreich P. The value of BNP testing. Arch Intern Med 2006;166:1063–4
   PubMedGoogle Scholar
• Gray J. The use of B-type natriuretic peptide to diagnose congestive heart failure. Clin Lab Sci 2006;19:214–7
   PubMedGoogle Scholar
• Dispenzieri A, Kyle R, Gertz M, Therneau T, Miller W, Chandrasekaran K, McConnell JP, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787–9
   PubMed Web of Science ®Google Scholar
• Kristen A, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, Merkle C, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010;116:2455–61
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440–63
   PubMed Web of Science ®Google Scholar
• Devereux RB, de Simone G, Koren MJ, Roman MJ, Laragh JH. Left ventricular mass as a predictor of development of hypertension. Am J Hypertens 1991;4:603S–7S
   Web of Science ®Google Scholar
• Damy T, Viallet C, Lairez O, Deswarte G, Paulino A, Maison P, Vermes E, et al. Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure. Eur J Heart Fail 2009;11:818–24
   PubMed Web of Science ®Google Scholar
• Youden W. An index for rating diagnostic tests. Cancer 1950;3:32–5
   PubMed Web of Science ®Google Scholar
• Juneblad K, Näslund A, Olofsson B, Suhr O. Outcome of exercise electrocardiography in familial amyloidotic polyneuropathy patients, Portuguese type, under evaluation for liver transplantation. Amyloid 2004;11:208–13
   PubMed Web of Science ®Google Scholar
• Dokainish H. Tissue Doppler imaging in the evaluation of left ventricular diastolic function. Curr Opin Cardiol 2004;19:437–41
   PubMed Web of Science ®Google Scholar
• Nahum J, Bensaid A, Dussault C, Macron L, Clemence D, Bouhemad B, Monin JL, et al. Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients. Circ Cardiovasc Imaging 2010;3:249–56
   PubMed Web of Science ®Google Scholar
• Liu D, Niemann M, Hu K, Herrmann S, Störk S, Knop S, Ertl G, et al. Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis. Am J Cardiol 2011;108:591–8
   PubMed Web of Science ®Google Scholar
• Vasan R. Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations. Circulation 2006;113:2335–62
   PubMed Web of Science ®Google Scholar
• Nagueh S, Middleton K, Kopelen H, Zoghbi W, Quiñones M. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997;30:1527–33
   PubMed Web of Science ®Google Scholar
• Nagueh S, Lakkis N, Middleton K, Spencer W, Zoghbi W, Quiñones M. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999;99:254–61
   PubMed Web of Science ®Google Scholar
• Nagueh S, Appleton C, Gillebert T, Marino P, Oh J, Smiseth O, Waggoner AD, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107–133
   PubMed Web of Science ®Google Scholar
• Takemura G, Takatsu Y, Doyama K, Itoh H, Saito Y, Koshiji M, Ando F, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 1998;15:754–65
   Google Scholar
• Nordlinger M, Barbarajean Magnani M, Skinner M, Falk R. Is Elevated Plasma B-Natriuretic Peptide in Amyloidosis Simply a Function of the Presence of Heart Failure? Am J Cardiol 2005;96:982–4
   PubMed Web of Science ®Google Scholar
• Lehrke S, Steen H, Kristen A, Merten C, Lossnitzer D, Dengler T, Katus HA, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid 2009;16:187–95
   PubMed Web of Science ®Google Scholar
• Suhr O, Anan I, Backman C, Karlsson A, Lindqvist P, Mörner S, Waldenström A. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008;263:294–301
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert J, White HD, Infarction JEAAWTFftRoM. Universal definition of myocardial infarction. Circulation 2007;116:2634–53
   PubMed Web of Science ®Google Scholar
• Jaffe A, Ravkilde J, Roberts R, Naslund U, Apple F, Galvani M, Katus H. It's time for a change to a troponin standard. Circulation 2000;102:1216–20
   PubMed Web of Science ®Google Scholar
• Katus H, Remppis A, Neumann F, Scheffold T, Diederich K, Vinar G, Noe A, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991;83:902–12
   PubMed Web of Science ®Google Scholar
• Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus H. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol 2006;48:2192–4
   PubMed Web of Science ®Google Scholar
• Miller W, Wright R, Mc Gregor C. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. Am J Cardiol 2001;88:813–5
   PubMed Web of Science ®Google Scholar